MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
31 janv. 2024 05h00 HE
|
AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
BioNTech und DualityBio starten zulassungsrelevante Phase-3-Studie mit Antikörper-Wirkstoff-Konjugat-Kandidat BNT323/DB-1303 bei metastasiertem Brustkrebs
22 janv. 2024 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie mit BNT323/DB-1303 basiert auf positiven Daten zur Sicherheit und Wirksamkeit aus einer Phase-1/2-Studie bei Brustkrebspatientinnen und -patienten mit...
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22 janv. 2024 06h45 HE
|
BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18 janv. 2024 07h00 HE
|
HilleVax, Inc.
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 janv. 2024 07h15 HE
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
12 janv. 2024 08h45 HE
|
International Myeloma Foundation
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at ASH 2023
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
08 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
08 janv. 2024 07h00 HE
|
HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
08 janv. 2024 07h00 HE
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
05 janv. 2024 04h00 HE
|
AKAMPION
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...